New Delhi, Dec 06 : Biocon Ltd has announced a comprehensive capital plan worth ₹11,450 crore to accelerate the integration of its biologics operations and strengthen its position as a global biopharmaceutical leader. The strategic initiative is aimed at consolidating manufacturing, enhancing supply chain efficiency, and enabling long-term growth in biosimilars and advanced biologics.
The company said the capital plan will support infrastructure upgrades, capacity expansion, and operational integration of its various biologics units a move expected to boost productivity and streamline processes across its global network. The initiative also aligns with Biocon’s broader strategy to scale its biologics portfolio and respond to increasing worldwide demand.
Industry experts note that the investment marks a significant step for Biocon as it prepares for the next phase of global competition in the biosimilars market, where cost efficiency and integrated production capabilities are key differentiators.
The capital plan is expected to be rolled out in phases, with Biocon focusing on strengthening manufacturing capabilities, regulatory compliance, and research driven expansion. The company believes the move will enhance its ability to bring high-quality, affordable biologics to markets worldwide.